Stimulant Treatment Patterns and Compliance in Children and Adults With Newly Treated Attention-Deficit/Hyperactivity Disorder

Perwien, Amy R.; Hall, Jennifer; Swensen, Andrine R.; Swindle, Ralph

doi:10.18553/jmcp.2004.10.2.122

Cited by 123 publications

(119 citation statements)

References 27 publications

Supporting

Mentioning

109

Contrasting

Order By: Relevance

“…We anticipated this relatively short therapy period based on ap revious study by Perwien et al, which concluded that even though ADHD patients continued their ADHD medication for several months, they did not consistently take medication for morethan 2months. 24 Second, our study did not directly assess the clinical severity of ADHD. Like all administrative claims databases, ADHD severity could not be determined from the data that we accessed.…”

Section: Limitationsmentioning

confidence: 99%

“…We included ICD-9-CM codes 314.00 (attentiondeficit disorder without hyperactivity,a lso known as ADD of predominantly the inattentive type 38 )a nd 314.0 (nonspecific attention-deficit disorder) as well as 314.01, which is specific to attention-deficit disorder with hyperactivity (ADHD). While other researchers have used ICD-9-CM codes 314.0x to describe ADHD, 24,25 the correct definition of code 314.0x is ADD because ICD-9-CM code 314.00 is intended to specify ADD without hyperactivity.A si st rue of much of the research in this area, we did not analyze the data with respect to the use of ICD-9-CM code 314.00 versus 314.01.…”

Section: Limitationsmentioning

confidence: 99%

“…9 Depression was found to be the most common comorbid condition among patients with ADHD. 24 Another study reported that patients weremorelikely to receive atomoxetine compared with stimulants if they had aprior historyofbipolar disorder,anxiety, substance abuse, or antidepressant use. 25 The Charlson Comorbidity Index is aw eighted sum of 17 comorbidities in which comorbidity weights areb ased on adjusted risk of 1-year mortality; the higher the Charlson Comorbidity Index, the higher the illness burden.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Health Care Costs of Adults Treated for Attention-Deficit/Hyperactivity Disorder Who Received Alternative Drug Therapies

Wu¹,

Birnbaum²,

Zhang³

et al. 2007

JMCP

View full text Add to dashboard Cite

Section: Limitationsmentioning

confidence: 99%

Section: Limitationsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Health Care Costs of Adults Treated for Attention-Deficit/Hyperactivity Disorder Who Received Alternative Drug Therapies

Wu¹,

Birnbaum²,

Zhang³

et al. 2007

JMCP

View full text Add to dashboard Cite

“…[10][11][12][13] In 1s tudy, BACKGROUND: Although stimulant therapyiscommonly discontinued early in adults with attention-deficit/hyperactivity disorder (ADHD), the factors that contribute to continuity of stimulant therapyremain largely unknown.…”

mentioning

confidence: 99%

Continuity in Methylphenidate Treatment of Adults With Attention-Deficit/Hyperactivity Disorder

Olfson¹,

Marcus²,

Zhang³

et al. 2007

JMCP

View full text Add to dashboard Cite

ReseaRch Int he general adult population, the prevalence of attentiondeficit/hyperactivity disorder (ADHD) is approximately 2% to 4%. [1][2][3][4] Methylphenidate (MPH) effectively ameliorates many symptoms of adult ADHD. [5][6][7][8][9] In 1l arge 6-week randomized controlled trial of adults with ADHD,7 immediate-release methylphenidate (IR-MPH) was associated with a76% response rate, compared with a1 9% response rate for placebo. In a 6-week trial with the same response criteria, 66% of subjects treated with osmotic release oral system methylphenidate (OROS-MPH) responded, compared with 39% who received placebo. 9In both studies, response was defined as a3 0% symptom reduction and, at least, much overall improvement.Early discontinuation of treatment is common in the community careo fp atients initiating stimulant therapy. [10][11][12][13] In 1s tudy, BACKGROUND: Although stimulant therapyiscommonly discontinued early in adults with attention-deficit/hyperactivity disorder (ADHD), the factors that contribute to continuity of stimulant therapyremain largely unknown.OBJECTIVE: To (1) comparethe continuity of methylphenidate (MPH) therapy among adults who use immediate-release methylphenidate (IR-MPH) for ADHD with adults who use extended-release methylphenidate (ER-MPH) formulations, and (2) RESULTS: Less than one third(30.0%) of the adult patients who were prescribed MPH had 1ormoremedical claims with adiagnosis code for ADHD.For the adult MPH patients with at least 1medical claim with a diagnosis code for ADHD,the patients who initiated therapywith ER-MPH (N =2,833) weresignificantly younger,weremorelikely to be male,and were less likely to be treated by apsychiatrist than werethe patients who initiated therapywith IR-MPH (N =2,289). Only 50.5% (n =1,156) of IR-MPH patients and 61.4% (n =1,739) of ER-MPH patients had morethan 1pharmacyclaim for the indexMPH medication. Adults treated with ER-MPH also had a significantly longer median duration of treatment with the indexmedication (ER-MPH: 68 days, 95% confidence interval [CI], 65-71 days vs. IR-MPH 39 days, 95% CI, 33-52 days). Controlling for group differences in age,gender, treatment by apsychiatrist, recently prescribed psychotropic medications, treated mental disorders, emergencymental health treatment, and inpatient mental health care, ER-MPH initiation wasassociated with an average 27% longer duration of treatment than with IR-MPH (survival time ratio: 1.27, 95% CI, 1.20-1.35).CONCLUSION: In management of adult ADHD,use of ER-MPH formulations wasassociated with alonger median duration of the initially prescribed medication than wasuse of IR-MPH. It is unknown whether the observed absolute unadjusted difference of 29 days in median length of therapyis clinically important.

show abstract

“…Among the 735 included subjects (0-18 years of age), therapy switching was observed in 11.6%, and occurred on average 165.5 days (SD = 147.4) after initiation of ADHD pharmacotherapy (MPH 66.4%, amphetamine mixed salts 21.6%, dextroamphetamine 8.4%, pemoline 3.1%, methamphetamine 0.4%). The study did not specify to which medicines the patients were switched (Perwien et al 2004). A study by Sanchez et al used data from the Texas Medicaid Vendor Drug Program to investigate different adherence measures (including switching rates) in a population of 9449 patients (5-18 years of age) with ADHD starting stimulant treatment during [2001][2002].…”

mentioning

confidence: 99%

Switch in Therapy from Methylphenidate to Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: An Analysis of Patient Records

Warrer

Thomsen

Dalsgaard

et al. 2016

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

Stimulant Treatment Patterns and Compliance in Children and Adults With Newly Treated Attention-Deficit/Hyperactivity Disorder

Cited by 123 publications

References 27 publications

Health Care Costs of Adults Treated for Attention-Deficit/Hyperactivity Disorder Who Received Alternative Drug Therapies

Health Care Costs of Adults Treated for Attention-Deficit/Hyperactivity Disorder Who Received Alternative Drug Therapies

Continuity in Methylphenidate Treatment of Adults With Attention-Deficit/Hyperactivity Disorder

Switch in Therapy from Methylphenidate to Atomoxetine in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: An Analysis of Patient Records

Contact Info

Product

Resources

About